Nasdaq: $26.59 (-0.59) | AIM: £3.91 (-0.01)
News Archive

Our latest announcements or presentations are available by selecting the desired News Type.

Announcements can be further filtered by topic using the News Topic check boxes.

 

The full text of all announcements are available for download in the form of PDF files.  For convenience, the text of some announcements have been partially or fully rendered as web pages.  Should any inconsistencies exist, the PDF version shall prevail.

News Type
Presentations
RNS Announcements
News Topics
Group
Oncology / Immunology
Other Ventures
Regulatory Notice
1
23456
found Documents: 279
Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, May 4, 2021: HUTCHMED (China) Limited (Nasdaq/AIM: HCM), formerly known as Hutchison China MediTech Limited, announces that, further to its “Results of Annual General Meeting” announcement
Read More
– First NDA submission by HUTCHMED in the U.S.; product launch preparations underway –   Hong Kong, Shanghai & Florham Park, NJ — Monday, May 3, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces th
Read More
— Single-arm study in ~180 patients, with ORR as primary endpoint — — Relapsed/refractory FL and MZL constitute approximately 25% of all NHL — — HMPL-689 trials are also underway in these and other NHL subtypes in the U.S., Europe an
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Hong Kong, Shanghai & Florham Park, NJ — Thu
Read More
— HMPL-306 is the sixth innovative oncology drug candidate discovered in house by HUTCHMED to enter into global development —   Hong Kong, Shanghai & Florham Park, NJ — Monday, March 29, 2021: Hutchison China MediTech Limited (“HUT
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Friday, March 26, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that its 2020 Annual Report together with the Notice of Annual General Meeting and the Form of Pr
Read More
– Allows focus on China and global clinical development and market launches of key Oncology/Immunology assets –   Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, March 24, 2021: Hutchison China MediTech Limited (“HUTCHME
Read More
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 24, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated a Phase Ib/II study of surufatinib in combination with BeiGene’s tislelizumab in patients w
Read More
Today, we begin consolidating the two corporate identities that we have used since our inception.  Hutchison China MediTech, or Chi-Med, has been used as our group identity, while Hutchison MediPharma has been the identity of our novel drug R&D
Read More
Company to Host Annual Results Call & Webcast Today at 1 p.m. GMT / 8 a.m. EST / 9 p.m. HKT  Hong Kong, Shanghai & Florham Park, NJ––Thursday, March 4, 2021:  Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM), a
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, January 14, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presente
Read More
Hong Kong, Shanghai, San Diego & Florham Park, NJ: Monday, January 11, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”) today announce a strategic partnership to further dev
Read More
– Sulanda® is Chi-Med’s first oncology drug brought to market without a partnership and the company’s second oncology drug approved in China – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression o
Read More
– Company plans to complete rolling submission in the first half of 2021 – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acce
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, December 22, 2020:  Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 39th Annual JP Morgan Heal
Read More
Tuesday, December 8, 2020 Shanghai: Chi-Med (Nasdaq/AIM: HCM) today held a ground-breaking ceremony in Zhangjiang Hi-Tech Park, Shanghai, commencing construction of a large-scale manufacturing plant for innovative drugs. Representatives from the S
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Hong Kong, Shanghai, & Florham Park, NJ: Tuesday
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, November 5, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that initial analysis of the first in human HMPL-689 Phase I dose escalation study will be pre
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Friday, October 30, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, will present or participate in the
Read More
  ― Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”) ―   ― SANET-p results complement previously presented positive Pha
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 17, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treatment of patients with
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Friday, September 4, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated FRESCO-2, a Phase III registration study of fruquintinib for the treatment of patients with metas
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Thursday, September 3, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth fa
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Monday, August 24, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the studies of surufatinib and fruquintinib will be presented
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Monday, August 10, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it received scientific advice from the European Medicines Agency's (“EMA”) Committee for
Read More
– Strong global pipeline progress – three U.S. FDA1 Fast Track Designations; surufatinib U.S. NDA2 preparations underway; and initiation of global Phase III for fruquintinib –  – Two further NDAs submitted in China – savolitinib in
Read More
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today announce an amendment to the 2013 License and Collaboration Agreeme
Read More
Hong Kong, Shanghai & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products Administration (“NMPA”) has granted Priority Review st
Read More
  — HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med —   Hong Kong, Shanghai & Florham Park, NJ: Friday, July 24, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has in
Read More
London: Friday, June 26, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its interim results for the six months ended June 30, 2020 on Thursday, July 30, 2020 at 12:00 noon British Summer Time (BST) (7:00 p
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   – Strategic investment demonstrates General Atlant
Read More
London: Thursday, June 18, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation for the development of fruquintinib, for th
Read More
London: Tuesday, June 9, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), its 50:50 joint venture with Guangzhou Baiyu
Read More
London: Thursday, June 4, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the Independent Data Monitoring Committee (IDMC) of the FRUTIGA study of fruquintinib has completed a planned interim data review.
Read More
London: Monday June 1, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it has held its pre-New Drug Application (“NDA”) meeting with the U.S. Food and Drug Administration (“FDA”) for surufatinib f
Read More
Press Release   — First NDA filing of savolitinib globally — —  Chi-Med seeking first-in-class Chinese marketing authorization for a selective MET inhibitor —   London: Friday, May 29, 2020: Hutchison China MediTech Limi
Read More
Press Release   ― Savolitinib in MET exon 14 skipping NSCLC efficacy evaluable patients demonstrated 49.2% ORR, 93.4% DCR and 9.6 months DoR, including 36% patients with more aggressive disease subtype ― ― Savolitinib vs. sunitinib stu
Read More
Press Release   – Collaboration to explore multiple solid tumor cancer indications – – Initial development focused on multi-cohort trials in the U.S., Europe, China and Australia –   LONDON, UK; CAMBRIDGE, Mass. and BEIJING
Read More
London: Thursday, May 14, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of savolitinib, surufatinib, and fruquintinib will be presented at the upcoming AS
Read More
London: Monday, May 11, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Healt
Read More
London: Wednesday, April 22, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of surufatinib will be presented at the upcoming American Association for Cance
Read More
London: Friday, April 17, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted two Fast Track Designations for the development of surufatinib, for
Read More
London: Tuesday, March 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors (“FGFR”), in patients
Read More
London: Wednesday, March 25, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/ AIM: HCM) today announces that its 2019 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy (“AGM Materials”) have bee
Read More
Company to Host Annual Results Conference Call Today at 1:00 p.m. GMT / 8:00 a.m. EST / 9:00 p.m. HKT   London: Tuesday, March 3, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM), a commercial-stage biopharmaceutical comp
Read More
London: Tuesday, February 25, 2020: Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that its final results for the year ended December 31, 2019 will be released on Tuesd
Read More
Press Release London: Monday, February 10, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of updated results from the Phase II CALYPSO study of the savolitinib / Imfinzi® (durvalumab) combi
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Thursday, February 6, 2020: Hutchiso
Read More
The announcement has been updated on February 25, please see the updated announcement here. London: Friday, January 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended Decem
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Thursday, January 23, 2020: Hutchiso
Read More